Solana Company Class A Common Stock (DE)
HSDTHelius Medical Technologies, Inc. is a neurotech company focused on developing and commercializing non-invasive neuromodulation therapies to improve brain function and recovery. Their flagship product, the Portable Neuromodulation Stimulator (PoNS), aims to enhance neuroplasticity and aid in rehabilitation for patients with neurological conditions such as traumatic brain injury and stroke. The company emphasizes innovative solutions to address unmet needs in neurological healthcare.
Company News
Helius Medical Technologies filed a 510(k) submission to the FDA seeking expanded indication for its PoNS device to treat gait and balance deficits in chronic stroke patients, based on clinical trials demonstrating statistically significant improvements in functional gait assessment.
Helius Medical Technologies, Inc. announced the pricing of its public offering of 2,768,600 shares of Class A common stock and warrants to purchase up to 2,768,600 shares of common stock at a combined public offering price of $3.27 per share and accompanying warrants. The offering is expected to raise gross proceeds of $9.1 million.
Helius Medical Technologies has exceeded its initial enrollment target for its stroke registrational program, with 128 participants enrolled as of December 31, 2024. The company expects to reach the maximum enrollment of 150 participants by the end of January 2025 and is on track to submit for FDA authorization for the PoNS device in the stroke i...
Helius Medical Technologies, a neurotech company, announced its plans to participate in The ThinkEquity Conference on October 30, 2024, where management will present and hold one-on-one investor meetings.
Helius Medical Technologies announced updates on reimbursement determinations from CMS for its PoNS device. CMS set the reimbursement rate for the PoNS Mouthpiece at $2,963.30, which Helius plans to challenge. CMS deferred the final determination for the PoNS Controller to the next cycle.
